Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Mar 17, 2025
Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025
Commercial launch in the PRC of generic nintedanib for the treatment of IPF and avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia expected in 2025
Read more at globenewswire.com9.07
-0.39 (-4.12%)
Find more stocks in the Stock Screener
GYRE Latest News and Analysis
9 days ago - ChartmillLet's have a look at the top gainers and losers one hour before the close of the markets of today's session.Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.
9 days ago - ChartmillLet's take a look at the stocks that are in motion in today's session.Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
10 days ago - ChartmillDiscover the top movers in Friday's pre-market session.As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
10 days ago - ChartmillThursday's after hours session: top gainers and losersAs the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
